Our morning reception in the legislative dining room at Queen’s Park on November 7, 2019 was attended by nearly 100 patients, caregivers, survivors, cancer patient groups, MPPs, including three ministers and several staffers, and others.
Earlier this month, CCSN welcomed Owen Brady, our new Partnership & Fundraising Manger. Having multiple years of experience working in the non-profit sector, Owen brings a wealth of expertise in fundraising, partnership management, and community engagement to his role.
The Canadian Cancer Survivor Network has designed an online course which will help prepare you for a variety of exciting opportunities to have your own voice heard within healthcare discourses and practices.
Information about breast density is an important part of breast cancer screening and ensuring early detection and treatment. That is why it will now be automatically included in a woman’s screening mammography report. Nova Scotia is the first province in Canada to use a software that assesses breast density and automatically shares results. “Breast health is a serious issue and it’s important to make sure
Date: October 7, 2019 Our file number: 19-119291-196 The purpose of this Notice of Amendment is to notify about the additions of acalabrutinib, galcanezumab, larotrectinib, mannitol, neratinib, niraparib, ravulizumab, romosozumab, and sodium zirconium cyclosilicate to the Prescription Drug List (PDL) for human and veterinary use. These additions are effective at the time of posting. Rationale: A scientific review of these drugs against the criteria set out in
Clinical Trials Ontario (CTO) has been working with health charities and patient organizations like CCSN to build tools and resources about clinical trials that are informed by and meet the needs of their communities. CCSN is one of the organizations that has been engaged from the start of these efforts, and this update is intended to help you see what this collaborative work has produced.